Request for Information: Building A 21st Century Bioeconomy, 62869-62871 [2011-26088]
Download as PDF
<![CDATA[
Federal Register / Vol. 76, No. 196 / Tuesday, October 11, 2011 / Notices
operating license. The agency afforded
an opportunity for hearing in the Notice
of Opportunity for Hearing published in
the Federal Register on June 28, 2010
(75 FR 36717–36721). The NRC received
no request for a hearing or petition for
leave to intervene following the notice.
The NRC staff prepared a safety
evaluation report for the renewal of
Facility Operating License No. R–76 and
concluded, based on that evaluation, the
licensee can continue to operate the
facility without endangering the health
and safety of the public. The NRC staff
also prepared an Environmental
Assessment and Finding of No
Significant Impact for the renewal of the
facility operating license, noticed in the
Federal Register on April 19, 2011 (76
FR 2192821931), and concluded that
renewal of the facility operating license
will not have a significant impact on the
quality of the human environment.
Dated at Rockville, Maryland, this 30th day
of September, 2011.
For The Nuclear Regulatory Commission.
Patricia A. Silva,
Acting Chief, Research and Test Reactors
Licensing Branch, Division of Policy and
Rulemaking, Office of Nuclear Reactor
Regulation.
[FR Doc. 2011–26180 Filed 10–7–11; 8:45 am]
BILLING CODE 7590–01–P
Sunshine Notice—October 27, 2011
Board of Directors Meeting
Thursday, October 27,
2011, 10 a.m. (Open Portion) 10:15 a.m.
(Closed Portion).
PLACE: Offices of the Corporation,
Twelfth Floor Board Room, 1100 New
York Avenue, NW., Washington, DC.
STATUS: Meeting OPEN to the Public
from 10 a.m. to 10:15 a.m. Closed
portion will commence at 10:15 a.m.
(approx.).
MATTERS TO BE CONSIDERED:
1. President’s Report
2. Tribute—Christopher J. Hanley
FURTHER MATTERS TO BE CONSIDERED:
(Closed to the Public 10:15 a.m.)
1. Reports
2. Revisions to OPIC Bylaws
3. Revised Delegation of Authority
4. Finance Project—Egypt and South
Sudan (upon the opening of OPIC
Programs)
5. Finance Project—Guatemala
6. Finance Project—Peru
7. Finance Project—Mexico
8. Finance Project—Global
mstockstill on DSK4VPTVN1PROD with NOTICES
TIME AND DATE:
20:47 Oct 07, 2011
Dated: October 5, 2011.
Connie M. Downs,
Corporate Secretary, Overseas Private
Investment Corporation.
[FR Doc. 2011–26302 Filed 10–6–11; 4:15 pm]
BILLING CODE 3210–01–P
OFFICE OF SCIENCE AND
TECHNOLOGY POLICY
Request for Information: Building A
21st Century Bioeconomy
Notice of Request for
Information (RFI).
ACTION:
The purpose of this Request
for Information (RFI) is to solicit input
from all interested parties regarding
recommendations for harnessing
biological research innovations to meet
national challenges in health, food,
energy, and the environment while
creating high-wage, high-skill jobs.
The public input provided through
this Notice will inform the Office of
Science and Technology Policy (OSTP)
as it works with Federal agencies and
other stakeholders to develop a National
Bioeconomy Blueprint.
DATES: October 7, 2011—December 6,
2011.
ADDRESSES:
BIOECONOMY@OSTP.GOV.
SUPPLEMENTARY INFORMATION:
SUMMARY:
OVERSEAS PRIVATE INVESTMENT
CORPORATION
VerDate Mar<15>2010
9. Finance Project—Mexico, Ukraine,
Brazil, Colombia, Jamaica, Egypt,
Vietnam, India and Nigeria
10. Finance Project—Sierra Leone,
Liberia, other West Africa countries
11. Finance Project—Sub-Saharan
Africa
12. Finance Project—Global
13. Pending Major Projects
Written summaries of the projects to
be presented will be posted on OPIC’s
Web site on or about October 7, 2011.
CONTACT PERSON FOR INFORMATION:
Information on the meeting may be
obtained from Connie M. Downs at (202)
336–8438.
Jkt 226001
Purpose
The purpose of this Request for
Information (RFI) is to solicit input from
all interested parties regarding
recommendations for harnessing
biological research innovations to meet
national challenges in health, food,
energy, and the environment while
creating high-wage, high-skill jobs.
The public input provided through
this Notice will inform the Office of
Science and Technology Policy as it
works with Federal agencies and other
stakeholders to develop a National
Bioeconomy Blueprint.
PO 00000
Frm 00115
Fmt 4703
Sfmt 4703
62869
Background
On September 16, 2011, President
Obama announced that his
Administration will develop a National
Bioeconomy Blueprint detailing
Administration-wide steps to harness
biological research innovations to
address national challenges in health,
food, energy, and the environment.
Biological research underpins the
foundation of a significant portion of
our economy. By better leveraging our
national investments in biological
research and development, the
Administration will grow the jobs of the
future and improve the lives of all
Americans.
Twenty-first century advances in
biological research and technologies are
poised to return tremendous public
benefits. For example, advances in
human genome-informed personalized
medicine and data analytics could be
combined to improve human health in
novel ways. In bio-based industry,
biological design can create new
opportunities for biofuels, chemicals,
materials, and energy-efficient
manufacturing processes.
The National Bioeconomy Blueprint
will identify strategies to meet grand
challenges, promote commercialization
and entrepreneurship, focus research
and development investments in areas
that will provide the foundation for the
bioeconomy, expand workforce training
to prepare the next generation of
scientists and engineers for the
bioeconomy jobs of the future, identify
regulatory reforms that will reduce
unnecessary burdens on innovators
while protecting health and safety, and
describe appropriate public-private
partnerships to accelerate innovation in
key areas.
OSTP seeks comment on the
questions listed below to inform the
development of the National
Bioeconomy Blueprint:
Grand challenges: President Obama
has identified ‘‘grand challenges’’ as an
important element of his innovation
strategy, such as ‘‘smart anti-cancer
therapeutics that kill cancer cells and
leave their normal neighbors untouched;
early detection of dozens of diseases
from a saliva sample; personalized
medicine that enables the prescription
of the right dose of the right drug for the
right person; a universal vaccine for
influenza that will protect against all
future strains; and regenerative
medicine that can end the agonizing
wait for an organ transplant.’’
(1) Identify one or more grand
challenges for the bioeconomy in areas
such as health, energy, the environment,
and agriculture, and suggest concrete
E:\FR\FM\11OCN1.SGM
11OCN1
mstockstill on DSK4VPTVN1PROD with NOTICES
62870
Federal Register / Vol. 76, No. 196 / Tuesday, October 11, 2011 / Notices
steps that would need to be taken by the
Federal government, companies, nonprofit organizations, foundations, and
other stakeholders to achieve this goal.
Research and development: R&D
investments, particularly in platform
technologies, can support advances in
health, energy, the environment, and
agriculture, and accelerate the pace of
discovery in fundamental life sciences
research.
(2) Constrained Federal budgets
require a focus on high-impact research
and innovation opportunities. With this
in mind, what should be the Federal
funding priorities in research,
technologies, and infrastructure to
provide the foundation for the
bioeconomy?
(3) What are the critical technical
challenges that prevent high throughput
approaches from accelerating
bioeconomy-related research? What
specific research priorities could
address those challenges? Are there
particular goals that the research
community and industry could rally
behind (e.g., NIH $1,000 genome
initiative 1)?
(4) The speed of DNA sequencing has
outstripped advances in the ability to
extract information from genomes given
the large number of genes of unknown
function in genomes; as many as 70% of
genes in a genome have poorly or
unknown functions. All areas of
scientific inquiry that utilize genome
information could benefit from
advances in this area. What new
multidisciplinary funding efforts could
revolutionize predictions of protein
function for genes?
Moving life sciences breakthroughs
from lab to market: It is a challenge to
commercialize advances in the life
sciences because of the risk, expense,
and need for many years of sustained
investment. The Administration is
interested in steps that it can take
directly, but is also interested in
encouraging experimentation with new
private-sector-led models for funding
commercialization of life sciences
research.
(5) What are the barriers preventing
biological research discoveries from
moving from the lab to commercial
markets? What specific steps can
Federal agencies take to address these
shortcomings? Please specify whether
these changes apply to academic labs,
government labs, or both.
(6) What specific changes to Federal
Small Business Innovation Research
(SBIR) and Small Business Technology
Transfer (STTR) programs 2 would help
1 https://www.genome.gov/27541190
2 https://www.sbir.gov/
VerDate Mar<15>2010
20:47 Oct 07, 2011
Jkt 226001
accelerate commercialization of
federally-funded bioeconomy-related
research?
(7) What high-value data might the
government release in the spirit of its
open government agenda that could
spur the development of new products
and services in the bioeconomy?
(8) What are the challenges associated
with existing private-sector models (e.g.
venture funding) for financing
entrepreneurial bioeconomy firms and
what specific steps can agencies take to
address those challenges?
Workforce development: Investment
in education and training is essential to
creating a technically-skilled 21st
century American bioeconomy
workforce.
(9) The majority of doctorate
recipients will accept jobs outside of
academia. What modifications should
be made to professional training
programs to better prepare scientists and
engineers for private-sector bioeconomy
jobs?
(10) What roles should community
colleges play in training the bioeconomy
workforce of the future?
(11) What role should the private
sector play in training future
bioeconomy scientists and engineers?
(12) What role might government,
industry, and academia play in
encouraging successful
entrepreneurship by faculty, graduate
students, and postdocs?
Reducing regulatory barriers to the
bioeconomy: As President Obama has
stated, our regulatory system must
‘‘identify and use the best, most
innovative, and least burdensome tools
for achieving regulatory ends’’ and
‘‘protect public health, welfare, safety,
and our environment while promoting
economic growth, innovation,
competitiveness, and job creation.’’
(13) What specific regulations are
unnecessarily slowing or preventing
bioinnovation? Please cite evidence that
the identified regulation(s) are a)
slowing innovation, and b) could be
reformed or streamlined while
protecting public health, safety, and the
environment.
(14) What specific steps can Federal
agencies take to improve the
predictability and transparency of the
regulatory system? (Please specify the
relevant agency.)
(15) What specific improvements in
the regulatory processes for drugs,
diagnostics, medical devices, and
agricultural biotechnology should
federal agencies implement? What
challenges do new or emerging
technologies pose to the existing
regulatory structure and what can
agencies do to address those challenges?
PO 00000
Frm 00116
Fmt 4703
Sfmt 4703
Public-private partnerships: The
Administration is interested in serving
as a catalyst for public-private
partnerships that build the bioeconomy
and address important unmet needs in
areas such as health, energy, agriculture,
and environment.
(16) What are the highest impact
opportunities for public-private
partnerships related to the bioeconomy?
What shared goals would these
partnerships pursue, which
stakeholders might participate, and
what mutually reinforcing commitments
might they make to support the
partnership?
(17) What are the highest impact
opportunities for pre-competitive
collaboration in the life sciences, and
what role should the government play
in developing them? What can be
learned from existing models for precompetitive collaboration both inside
and outside the life-sciences sector?
What are the barriers to such
collaborations and how might they be
removed or overcome?
Response to this RFI is voluntary.
Responders are free to address any or all
the above items, as well as provide
additional information that they think is
relevant to the development of a
National Bioeconomy Blueprint.
Please note that the Government will
not pay for response preparation or for
the use of any information contained in
the response.
How To Submit a Response
All comments must be submitted
electronically to: bioeconomy@ostp.gov.
Responses to this RFI will be accepted
through December 6, 2011. You will
receive an electronic confirmation
acknowledging receipt of your response,
but will not receive individualized
feedback on any suggestions. No basis
for claims against the U.S. Government
shall arise as a result of a response to
this request for information or from the
Government’s use of such information.
Responses received after the deadline
will be considered during
implementation of the activities of the
National Bioeconomy Blueprint if not
received before finalization of the
National Bioeconomy Blueprint.
Responses to the RFI, including the
names of the authors and their
institutional affiliations, will be posted
at https://www.whitehouse.gov/ostp/
bioeconomy.
Inquiries
Specific questions about this RFI
should be directed to the following email address: bioeconomy@ostp.gov.
Form should include:
[Assigned ID #]
E:\FR\FM\11OCN1.SGM
11OCN1
Federal Register / Vol. 76, No. 196 / Tuesday, October 11, 2011 / Notices
[Assigned Entry date]
Name/E-mail
Affiliation/Organization
City, State
Comment 1
Comment 2
Comment 3
Comment 4
Comment 5
Attachment
Ted Wackler,
Deputy Chief of Staff.
[FR Doc. 2011–26088 Filed 10–7–11; 8:45 am]
BILLING CODE P
OFFICE OF SCIENCE AND
TECHNOLOGY POLICY
President’s Council of Advisors on
Science and Technology Meeting
Office of Science and
Technology Policy.
ACTION: Notice of meeting.
AGENCY:
This notice sets forth the
schedule and summary agenda for a
partially closed meeting of the
President’s Council of Advisors on
Science and Technology (PCAST), and
describes the functions of the Council.
Notice of this meeting is required under
the Federal Advisory Committee Act
(FACA), 5 U.S.C., App.
DATES: November 2, 2011.
ADDRESSES: The meeting will be held at
the Marriott Metro Center, 775 12th
Street NW., Ballroom Salon A,
Washington, DC.
FOR FURTHER INFORMATION CONTACT:
Information regarding the meeting
agenda, time, location, and how to
register for the meeting is available on
the PCAST Web site at: https://
whitehouse.gov/ostp/pcast. A live video
webcast and an archive of the webcast
after the event are expected to be
available at https://whitehouse.gov/ostp/
pcast. The archived video will be
available within one week of the
meeting. Questions about the meeting
should be directed to Dr. Deborah D.
Stine, PCAST Executive Director, at
dstine@ostp.eop.gov, (202) 456–6006.
Please note that public seating for this
meeting is limited and is available on a
first-come, first-served basis.
SUPPLEMENTARY INFORMATION: The
President’s Council of Advisors on
Science and Technology (PCAST) is an
advisory group of the nation’s leading
scientists and engineers, appointed by
the President to augment the science
and technology advice available to him
from inside the White House and from
cabinet departments and other Federal
agencies. See the Executive Order at
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
20:47 Oct 07, 2011
Jkt 226001
https://www.whitehouse.gov/ostp/pcast.
PCAST is consulted about and provides
analyses and recommendations
concerning a wide range of issues where
understandings from the domains of
science, technology, and innovation
may bear on the policy choices before
the President. PCAST is administered
by the Office of Science and Technology
Policy (OSTP). PCAST is co-chaired by
Dr. John P. Holdren, Assistant to the
President for Science and Technology,
and Director, Office of Science and
Technology Policy, Executive Office of
the President, The White House; and Dr.
Eric S. Lander, President, Broad
Institute of the Massachusetts Institute
of Technology and Harvard.
Type of Meeting: Open and Closed.
Proposed Schedule and Agenda: The
President’s Council of Advisors on
Science and Technology (PCAST) is
scheduled to meet in open session on
November 2, 2011 from 10 a.m. to 5
p.m.
Open Portion of Meeting: During this
open meeting, PCAST is tentatively
scheduled to hear from speakers who
will provide an overview of two
reports—one on innovation and job
creation, and another on governmentheld spectrum. In addition, several
agencies will update PCAST on the
implementation status of the
recommendations it made in its report
on nanotechnology. PCAST will also
receive an update on the status of
several of its studies. Additional
information and the agenda, including
any changes that arise, will be posted at
the PCAST Web site at: https://
whitehouse.gov/ostp/pcast.
Closed Portion of the Meeting: PCAST
may hold a closed meeting of
approximately 1 hour with the President
on November 2, 2011, which must take
place in the White House for the
President’s scheduling convenience and
to maintain Secret Service protection.
This meeting will be closed to the
public because such portion of the
meeting is likely to disclose matters that
are to be kept secret in the interest of
national defense or foreign policy under
5 USC 552b(c)(1).
Public Comments: It is the policy of
the PCAST to accept written public
comments of any length, and to
accommodate oral public comments
whenever possible. The PCAST expects
that public statements presented at its
meetings will not be repetitive of
previously submitted oral or written
statements.
The public comment period for this
meeting will take place on November 2,
2011 at a time specified in the meeting
agenda posted on the PCAST Web site
at https://whitehouse.gov/ostp/pcast.
PO 00000
Frm 00117
Fmt 4703
Sfmt 9990
62871
This public comment period is designed
only for substantive commentary on
PCAST’s work, not for business
marketing purposes.
Oral Comments: To be considered for
the public speaker list at the meeting,
interested parties should register to
speak at https://whitehouse.gov/ostp/
pcast, no later than 12 p.m. Eastern
Time on October 24, 2011. Phone or email reservations will not be accepted.
To accommodate as many speakers as
possible, the time for public comments
will be limited to two (2) minutes per
person, with a total public comment
period of 30 minutes. If more speakers
register than there is space available on
the agenda, PCAST will randomly select
speakers from among those who
applied. Those not selected to present
oral comments may always file written
comments with the committee. Speakers
are requested to bring at least 25 copies
of their oral comments for distribution
to the PCAST members.
Written Comments: Although written
comments are accepted until the date of
the meeting, written comments should
be submitted to PCAST no later than 12
p.m. Eastern Time on October 17, 2011,
so that the comments may be made
available to the PCAST members prior
to the meeting for their consideration.
Information regarding how to submit
comments and documents to PCAST is
available at https://whitehouse.gov/ostp/
pcast in the section entitled ‘‘Connect
with PCAST.’’
Please note that because PCAST
operates under the provisions of FACA,
all public comments and/or
presentations will be treated as public
documents and will be made available
for public inspection, including being
posted on the PCAST Web site.
Meeting Accomodations: Individuals
requiring special accommodation to
access this public meeting should
contact Dr. Stine at least ten business
days prior to the meeting so that
appropriate arrangements can be made.
Ted Wackler,
Deputy Chief of Staff.
[FR Doc. 2011–26151 Filed 10–7–11; 8:45 am]
BILLING CODE 3170–12–P
E:\FR\FM\11OCN1.SGM
11OCN1
]]>Agencies
[Federal Register Volume 76, Number 196 (Tuesday, October 11, 2011)]
[Notices]
[Pages 62869-62871]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-26088]
=======================================================================
-----------------------------------------------------------------------
OFFICE OF SCIENCE AND TECHNOLOGY POLICY
Request for Information: Building A 21st Century Bioeconomy
ACTION: Notice of Request for Information (RFI).
-----------------------------------------------------------------------
SUMMARY: The purpose of this Request for Information (RFI) is to
solicit input from all interested parties regarding recommendations for
harnessing biological research innovations to meet national challenges
in health, food, energy, and the environment while creating high-wage,
high-skill jobs.
The public input provided through this Notice will inform the
Office of Science and Technology Policy (OSTP) as it works with Federal
agencies and other stakeholders to develop a National Bioeconomy
Blueprint.
DATES: October 7, 2011--December 6, 2011.
ADDRESSES: BIOECONOMY@OSTP.GOV.
SUPPLEMENTARY INFORMATION:
Purpose
The purpose of this Request for Information (RFI) is to solicit
input from all interested parties regarding recommendations for
harnessing biological research innovations to meet national challenges
in health, food, energy, and the environment while creating high-wage,
high-skill jobs.
The public input provided through this Notice will inform the
Office of Science and Technology Policy as it works with Federal
agencies and other stakeholders to develop a National Bioeconomy
Blueprint.
Background
On September 16, 2011, President Obama announced that his
Administration will develop a National Bioeconomy Blueprint detailing
Administration-wide steps to harness biological research innovations to
address national challenges in health, food, energy, and the
environment. Biological research underpins the foundation of a
significant portion of our economy. By better leveraging our national
investments in biological research and development, the Administration
will grow the jobs of the future and improve the lives of all
Americans.
Twenty-first century advances in biological research and
technologies are poised to return tremendous public benefits. For
example, advances in human genome-informed personalized medicine and
data analytics could be combined to improve human health in novel ways.
In bio-based industry, biological design can create new opportunities
for biofuels, chemicals, materials, and energy-efficient manufacturing
processes.
The National Bioeconomy Blueprint will identify strategies to meet
grand challenges, promote commercialization and entrepreneurship, focus
research and development investments in areas that will provide the
foundation for the bioeconomy, expand workforce training to prepare the
next generation of scientists and engineers for the bioeconomy jobs of
the future, identify regulatory reforms that will reduce unnecessary
burdens on innovators while protecting health and safety, and describe
appropriate public-private partnerships to accelerate innovation in key
areas.
OSTP seeks comment on the questions listed below to inform the
development of the National Bioeconomy Blueprint:
Grand challenges: President Obama has identified ``grand
challenges'' as an important element of his innovation strategy, such
as ``smart anti-cancer therapeutics that kill cancer cells and leave
their normal neighbors untouched; early detection of dozens of diseases
from a saliva sample; personalized medicine that enables the
prescription of the right dose of the right drug for the right person;
a universal vaccine for influenza that will protect against all future
strains; and regenerative medicine that can end the agonizing wait for
an organ transplant.''
(1) Identify one or more grand challenges for the bioeconomy in
areas such as health, energy, the environment, and agriculture, and
suggest concrete
[[Page 62870]]
steps that would need to be taken by the Federal government, companies,
non-profit organizations, foundations, and other stakeholders to
achieve this goal.
Research and development: R&D investments, particularly in platform
technologies, can support advances in health, energy, the environment,
and agriculture, and accelerate the pace of discovery in fundamental
life sciences research.
(2) Constrained Federal budgets require a focus on high-impact
research and innovation opportunities. With this in mind, what should
be the Federal funding priorities in research, technologies, and
infrastructure to provide the foundation for the bioeconomy?
(3) What are the critical technical challenges that prevent high
throughput approaches from accelerating bioeconomy-related research?
What specific research priorities could address those challenges? Are
there particular goals that the research community and industry could
rally behind (e.g., NIH $1,000 genome initiative \1\)?
---------------------------------------------------------------------------
\1\ https://www.genome.gov/27541190
---------------------------------------------------------------------------
(4) The speed of DNA sequencing has outstripped advances in the
ability to extract information from genomes given the large number of
genes of unknown function in genomes; as many as 70% of genes in a
genome have poorly or unknown functions. All areas of scientific
inquiry that utilize genome information could benefit from advances in
this area. What new multidisciplinary funding efforts could
revolutionize predictions of protein function for genes?
Moving life sciences breakthroughs from lab to market: It is a
challenge to commercialize advances in the life sciences because of the
risk, expense, and need for many years of sustained investment. The
Administration is interested in steps that it can take directly, but is
also interested in encouraging experimentation with new private-sector-
led models for funding commercialization of life sciences research.
(5) What are the barriers preventing biological research
discoveries from moving from the lab to commercial markets? What
specific steps can Federal agencies take to address these shortcomings?
Please specify whether these changes apply to academic labs, government
labs, or both.
(6) What specific changes to Federal Small Business Innovation
Research (SBIR) and Small Business Technology Transfer (STTR) programs
\2\ would help accelerate commercialization of federally-funded
bioeconomy-related research?
---------------------------------------------------------------------------
\2\ https://www.sbir.gov/
---------------------------------------------------------------------------
(7) What high-value data might the government release in the spirit
of its open government agenda that could spur the development of new
products and services in the bioeconomy?
(8) What are the challenges associated with existing private-sector
models (e.g. venture funding) for financing entrepreneurial bioeconomy
firms and what specific steps can agencies take to address those
challenges?
Workforce development: Investment in education and training is
essential to creating a technically-skilled 21st century American
bioeconomy workforce.
(9) The majority of doctorate recipients will accept jobs outside
of academia. What modifications should be made to professional training
programs to better prepare scientists and engineers for private-sector
bioeconomy jobs?
(10) What roles should community colleges play in training the
bioeconomy workforce of the future?
(11) What role should the private sector play in training future
bioeconomy scientists and engineers?
(12) What role might government, industry, and academia play in
encouraging successful entrepreneurship by faculty, graduate students,
and postdocs?
Reducing regulatory barriers to the bioeconomy: As President Obama
has stated, our regulatory system must ``identify and use the best,
most innovative, and least burdensome tools for achieving regulatory
ends'' and ``protect public health, welfare, safety, and our
environment while promoting economic growth, innovation,
competitiveness, and job creation.''
(13) What specific regulations are unnecessarily slowing or
preventing bioinnovation? Please cite evidence that the identified
regulation(s) are a) slowing innovation, and b) could be reformed or
streamlined while protecting public health, safety, and the
environment.
(14) What specific steps can Federal agencies take to improve the
predictability and transparency of the regulatory system? (Please
specify the relevant agency.)
(15) What specific improvements in the regulatory processes for
drugs, diagnostics, medical devices, and agricultural biotechnology
should federal agencies implement? What challenges do new or emerging
technologies pose to the existing regulatory structure and what can
agencies do to address those challenges?
Public-private partnerships: The Administration is interested in
serving as a catalyst for public-private partnerships that build the
bioeconomy and address important unmet needs in areas such as health,
energy, agriculture, and environment.
(16) What are the highest impact opportunities for public-private
partnerships related to the bioeconomy? What shared goals would these
partnerships pursue, which stakeholders might participate, and what
mutually reinforcing commitments might they make to support the
partnership?
(17) What are the highest impact opportunities for pre-competitive
collaboration in the life sciences, and what role should the government
play in developing them? What can be learned from existing models for
pre-competitive collaboration both inside and outside the life-sciences
sector? What are the barriers to such collaborations and how might they
be removed or overcome?
Response to this RFI is voluntary. Responders are free to address
any or all the above items, as well as provide additional information
that they think is relevant to the development of a National Bioeconomy
Blueprint.
Please note that the Government will not pay for response
preparation or for the use of any information contained in the
response.
How To Submit a Response
All comments must be submitted electronically to:
bioeconomy@ostp.gov.
Responses to this RFI will be accepted through December 6, 2011.
You will receive an electronic confirmation acknowledging receipt of
your response, but will not receive individualized feedback on any
suggestions. No basis for claims against the U.S. Government shall
arise as a result of a response to this request for information or from
the Government's use of such information.
Responses received after the deadline will be considered during
implementation of the activities of the National Bioeconomy Blueprint
if not received before finalization of the National Bioeconomy
Blueprint.
Responses to the RFI, including the names of the authors and their
institutional affiliations, will be posted at https://www.whitehouse.gov/ostp/bioeconomy.
Inquiries
Specific questions about this RFI should be directed to the
following e-mail address: bioeconomy@ostp.gov.
Form should include:
[Assigned ID ]
[[Page 62871]]
[Assigned Entry date]
Name/E-mail
Affiliation/Organization
City, State
Comment 1
Comment 2
Comment 3
Comment 4
Comment 5
Attachment
Ted Wackler,
Deputy Chief of Staff.
[FR Doc. 2011-26088 Filed 10-7-11; 8:45 am]
BILLING CODE P
